Table 3.
Percentage of Immune Cell Marker Positive Cell Populations
| Patient Study No. | CD163 (%) | CD8 (%) | CD4 (%) | PD-1 (%) | PAX5 (%) | PD-L1 Tumor (%) | PD-L1 Macrophage (%) | Radiographic Response | PFS (Months) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 03 | Pre | 25 | 2 | 1 | 0 | 1 | 0 | 0 | No | 7.3 |
| 03 | Post | NE | NE | NE | NE | NE | NE | NE | ||
| 24 | Pre | 10 | 5 | 2 | 1 | 1 | <1 | <1 | No | 7.4 |
| 24 | Post | NE | NE | NE | NE | NE | NE | NE | ||
| 04 | Pre | 5 | 1 | 1 | 0 | <1 | 0 | 15 | No | 5.6 |
| 04 | Post | 5 | 2 | 3 | 1 | 1 | 2 | 1 | ||
| 10 | Pre | 15 | 2 | 1 | <1 | <1 | 1 | 1 | No | 3.7 |
| 10 | Post | 15 | 5 | 1 | 0 | 1 | 0 | 1 | ||
| 19 | Pre | 15 | 2 | 1 | <1 | <1 | 2 | 1 | No | 5.4 |
| 19 | Post | 40 | 40 | 3 | 20 | 3 | 5 | 30 | ||
| 22 | Pre | 5 | 1 | <1 | <1 | 0 | 0 | 0 | No | 2.5a |
| 22 | Post | 5 | 1 | <1 | 0 | 0 | 0 | 0 |
Abbreviations: CD, cluster designation; NE, not evaluated; PAX5, paired box 5; PD-1, programmed death 1; PD-L1, programmed death ligand 1; pre, tumor sample obtained before anti-PD-1 therapy; post, tumor sample obtained after anti-PD-1 therapy.
aThis patient was censored at 2.5 months due to elective discontinuation of study therapy and continued to receive anti-PD-1 therapy on a compassionate use basis close to home without progression for 18 additional months.